COMMUNIQUÉS West-GlobeNewswire

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

16/09/2024 - 14:30

September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant Funds to Advance Development of Phase 3 Asset Biodexa Pharmaceuticals [...]

Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies

16/09/2024 - 14:30

Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

16/09/2024 - 14:05

Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a [...]

Corza Medical Appoints Jason Abair as Vice President of Legal & Chief Compliance Officer

16/09/2024 - 14:05

WESTWOOD, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Corza Medical (“Corza” or the “Company”) is pleased to announce the appointment of Jason Abair as its new Vice President, Legal & Chief Compliance Officer. With [...]

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

16/09/2024 - 14:05

Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism of action of NC410 [...]

Corza Medical nomme Jason Abair au poste de Vice-président du service juridique et Responsable de la conformité

16/09/2024 - 14:05

WESTWOOD, Mass., 16 sept. 2024 (GLOBE NEWSWIRE) -- Corza Medical (« Corza » ou la « Société ») a le plaisir d'annoncer la nomination de Jason Abair en tant que nouveau vice-président du service juridique et responsable [...]

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

16/09/2024 - 14:01

HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company’s Phase 2 clinical trial of barzolvolimab in [...]

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

16/09/2024 - 14:00

Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to receive bulk of $13.1 million grant funding Company anticipates [...]

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program

16/09/2024 - 14:00

Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies ROCKVILLE, Md., Sept. [...]

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

16/09/2024 - 14:00

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new [...]

Leading PACE Provider InnovAge Selected to Participate in National Study Focused on Preventing Falls by Seniors

16/09/2024 - 14:00

New LeaHD Study Advances as Industry Observes National PACE Awareness Month & Falls Prevention Month DENVER, Sept. 16, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), a leading Program [...]

Presentation at the 2024 International HBV Meeting Highlights Antiviral Activity of EBT-107 as a Potential Anti-HBV Therapy

16/09/2024 - 14:00

SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure deadly and debilitating [...]

Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity

16/09/2024 - 14:00

WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

16/09/2024 - 14:00

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% [...]

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

16/09/2024 - 14:00

BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

16/09/2024 - 14:00

Preclinical Study Highlight the Potential of Elraglusib in Overcoming FOLFIRINOX-induced Chemoresistance Through Downregulation of Epithelial to Mesenchymal Transition (EMT) Initial Data Demonstrates Early Evidence of [...]

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16/09/2024 - 14:00

BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today [...]

Extendicare Announces September 2024 Dividend of C$0.04 per Share

16/09/2024 - 14:00

MARKHAM, Ontario, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]

Canada's Only Single-Dose Cholera Vaccine Available Nationwide

16/09/2024 - 14:00

TORONTO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bavarian Nordic, a leading global supplier of travel vaccines, today announced the commercial availability of VAXCHORA ® —the only single-dose oral vaccine approved in Canada [...]